Bausch may have shed the Valeant name, but it still leans on price hikes: analyst

nyse
Bausch posted 3% organic growth in the second quarter to $2.15 billion. (Pixabay)

Bausch Healthcare may have changed its name from Valeant last year, but the company hasn’t gotten away from its often-criticized strategy of leaning on price increases, one analyst says. 

After digging into Bausch’s second-quarter results and a quarterly filing, Wells Fargo analyst David Maris wrote in a Friday note that it seems the company's still relying on “a price-driven model.” Without price hikes, the company’s second-quarter sales would’ve declined from last year, the analyst figures. 

Bausch reported second-quarter organic growth of 3%, reaching sales of $2.15 billion. Last quarter, the company posted 8% growth, Maris pointed out. In its quarterly filing, Bausch said it gained on higher pricing primarily in its Salix Pharmaceuticals unit, which sells drugs to treat gastrointestinal conditions. Xifaxan price hikes alone contributed $47 million to the top line, the filing says. 

Webinar

Bioavailability Enhancement – Industry Insights, Key Challenges & Advanced Development Solutions

Join this webcast on Tuesday, June 16 as experts present the exclusive survey findings and introduce innovative scalable drug delivery technologies proven to address the industry’s growing need for improving solubility and enhancing bioavailability.

Meanwhile, the company is still dealing with a heavy debt load and has an “underwhelming” pipeline, the analyst wrote.

“We believe the stock's -10% reaction since the earnings report versus the approximately flat S&P 500 is a reflection of what we consider disappointing results,” he added. 

Bausch has been trying to stabilize itself after its dramatic downfall as Valeant, and one of its moves was to change its scandal-plagued name.

Under the Valeant moniker, the company became notorious for buying up assets, cutting costs and raising prices. The strategy worked for awhile, and the stock soared as high as $257 in the summer of 2015. Later, thanks to government scrutiny and a specialty pharmacy scandal, the company's fortunes came crashing down and the stock fell under $10. More recently, the stock is trading at around $20.

RELATED: ‘Organic’ growth and ‘pivoting’ at Bausch Health? One analyst begs to disagree 

In a separate issue from second-quarter earnings, Maris’ team asked at a recent luncheon why Bausch’s R&D head Tage Ramakrishna hasn’t participated in earnings calls or conferences, he wrote. Basuch CEO Joseph Papa responded that Ramakrishna was on the company’s first-quarter 2016 earnings call, and said Ramakrishna has been “extremely busy,” according to the note. 

The analysts asked for more information about the R&D head, and management said “they would get back to us,” Maris wrote. 

Suggested Articles

AstraZeneca has signed a $750 million deal to produce up to 300 million doses of Oxford University's COVID-19 vaccine by year's end.

A new NEJM study found taking hydroxychloroquine after COVID-19 exposure doesn't reduce the risk of an infection. But questions remain.

Novartis is touting 52-week data for Cosentyx in spondyloarthritis––an indication where Eli Lilly's Taltz recently scored a trailblazing FDA approval.